Clinical Trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2021-12-17; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2025-05-14
Status change: Active, Not Recruiting → Recruiting 2024-12-02
Status change: Recruiting → Active, Not Recruiting 2023-11-19
Trial Details
NCT Number NCT05164094
Lead Sponsor ModernaTX, Inc.
Conditions Epstein-Barr Virus Infection
Enrollment 867 participants
Start Date 2021-12-28
Primary Completion 2026-10-05 (estimated)
Study Completion 2027-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-06